Profile data is unavailable for this security.
About the company
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.
- Revenue in CAD (TTM)269.38k
- Net income in CAD-2.88m
- Incorporated2006
- Employees--
- LocationBioasis Technologies Inc22420 Dewdney Trunk Road, Suite 300BURNABY V2X 3J5CanadaCAN
- Phone+1 (604) 295-7014
- Fax+1 (604) 278-8785
- Websitehttps://www.bioasis.us/contact/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| biOasis Technologies Inc | 269.38k | -2.88m | 395.13k | -- | -- | -- | -- | 1.47 | -0.0376 | -0.0376 | 0.0036 | -0.034 | 0.113 | -- | 7.24 | -- | -120.62 | -170.20 | -- | -2,618.50 | -- | -- | -1,067.57 | -224.22 | -- | -- | -- | -- | -99.07 | -40.66 | -523.83 | -- | -- | -- |
| Pontus Protein Ltd | 0.00 | -9.13m | 484.06k | -- | -- | 0.2214 | -- | -- | -0.1577 | -0.1577 | 0.00 | 0.0226 | 0.00 | -- | -- | -- | -126.32 | -- | -160.86 | -- | -- | -- | -- | -- | -- | -14.16 | 0.5126 | -- | -- | -- | -- | -- | -- | -- |
